
|Videos|July 27, 2021
How genomic testing can address accuracy issues with PSA screening and monitoring
Author(s)Urology Times staff
Brian T. Helfand, MD, PhD, discusses how the precision of genomic testing data can alleviate the accuracy issues associated with PSA testing for screening and monitoring prostate cancer.
Advertisement
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how the precision of genomic testing data can alleviate the accuracy issues associated with PSA testing for screening and monitoring prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC
2
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
3
Farah Rahman, MD, on monitoring resident wellness using biofeedback
4
John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC
5






